Shares of Silence Therapeutics plc (LON:SLN) hit a new 52-week high on Monday . The company traded as high as GBX 195 ($2.52) and last traded at GBX 187 ($2.42), with a volume of 139,762 shares. The stock had previously closed at GBX 176 ($2.27).

The firm has a 50 day moving average price of GBX 139.21 and a 200 day moving average price of GBX 103.81. The company’s market capitalization is GBX 130.53 million.

In related news, insider Andy Richards acquired 7,000 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was bought at an average price of GBX 147 ($1.90) per share, for a total transaction of £10,290 ($13,289.42). Also, insider Alistair Gray acquired 3,848 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was bought at an average price of GBX 130 ($1.68) per share, with a total value of £5,002.40 ($6,460.55).

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/04/silence-therapeutics-plc-sln-reaches-new-12-month-high-at-195-00.html.

Silence Therapeutics plc Company Profile

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.

Receive News & Stock Ratings for Silence Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics plc and related stocks with our FREE daily email newsletter.